Table 1.
Study demographics
| Author | Year | Treatment | Dosage | Control | Phase | N (T) | N (C) | Age (T/C) (median) | Sex (T/C) | Favorable (T/C) | Intermediate (T/C) | Poor (T/C) | Component |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Rini | 2019 | Atezolizumab plus bevacizumab | A 200 mg, B 15 mg/kg | S 50 mg | 3 | 454 | 461 | 62/60 | 318/350 | 89/90 | 311/318 | 54/53 | CC or Sa |
| Rini | 2016 | IMA901 plus sunitinib | I 4.13 mg, S 50 mg | S 50 mg | 3 | 204 | 135 | 61/60 | 142/88 | 56/35 | 145/96 | 3/4 | CC |
| Motzer | 2013 | Pazopanib | 800 mg | S 50 mg | 3 | 557 | 553 | 61/62 | 398/415 | 151/152 | 322/328 | 110/85 | CC |
| Plimack | 2020 | Pembrolizumab and axitinib | P 200 mg, Ax 5 mg | S 50 mg | 3 | 432 | 429 | 62/61 | 308/320 | 138/131 | 238/246 | 56/52 | CC or Sa |
| Motzer | 2019 | Nivolumab plus ipilimumab | N 3 mg/kg, Ip 1 mg/kg | S 50 mg | 3 | 550 | 546 | 62/62 | 413/395 | 125/124 | 334/333 | 91/89 | CC or Sa |
| Motzer | 2019 | Avelumab plus axitinib | Av 10 mg/kg, Ax 5 mg | S 50 mg | 3 | 442 | 444 | 62/61 | 316/344 | 96/100 | 283/293 | 51/45 | CC |
A Atezolizumab, Av avelumab, Ax axitinib, B bevacizumab, C control, CC clear cell, I IMA901, Ip ipilimumab, N nivolumab, P pembrolizumab, S sunitinib, Sa sarcomatoid, T treatment